Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Huai-liang Wu"'
Publikováno v:
Breast, Vol 70, Iss , Pp 63-69 (2023)
Background: Disease progression during neoadjuvant systemic therapy for breast cancer indicates poor prognosis, while predictors of the clinical outcomes of these patients remain unclear. By comparing the clinical outcomes of patients with different
Externí odkaz:
https://doaj.org/article/3459efedfd7948b2bdbc12f34beff57c
Publikováno v:
Breast, Vol 72, Iss , Pp 103589- (2023)
Background: Contralateral axillary lymph node metastasis (CAM) is rare. It remains controversial whether CAM should be regarded as a regional or distant metastatic disease. Our study aims to investigate the accurate clinical orientation and managemen
Externí odkaz:
https://doaj.org/article/ed2e116e0e1a47478e8d92e85ab8ab77
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-21 (2022)
Abstract Targeting nucleotide metabolism can not only inhibit tumor initiation and progression but also exert serious side effects. With in-depth studies of nucleotide metabolism, our understanding of nucleotide metabolism in tumors has revealed thei
Externí odkaz:
https://doaj.org/article/acad7d353ba54859b28b1b5d0389bb79
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
IntroductionLocoregional recurrent breast cancer indicates poor prognosis. No solid prediction model is available to predict prognosis and guide clinical management. Prior local treatment or systemic treatment remains controversial.MethodsLocoregiona
Externí odkaz:
https://doaj.org/article/46534088cd694165b151421e1bdcbf75
Publikováno v:
EClinicalMedicine, Vol 21, Iss , Pp - (2020)
Background: A novel coronavirus disease (COVID-19) outbreak due to the severe respiratory syndrome coronavirus (SARS-CoV-2) infection occurred in China in late December 2019. Facemask wearing with proper hand hygiene is considered an effective measur
Externí odkaz:
https://doaj.org/article/1d514cb5d2b04e1bbce42586ccf331ed
Publikováno v:
Theranostics; 2024, Vol. 14 Issue 9, p3548-3564, 17p
Publikováno v:
British Journal of Cancer. 128:638-646
Background The OlympiA trial demonstrated the benefits of adjuvant usage of olaparib for high-risk patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) and germline BRCA (gBRCA) mutation. This provoked thoughts on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::606f0a564186655de30239e2cb939482
https://doi.org/10.1038/s41416-022-02111-y
https://doi.org/10.1038/s41416-022-02111-y
Autor:
Peng Ji, Yue Gong, Ming-liang Jin, Huai-liang Wu, Lin-Wei Guo, Yu-Chen Pei, Wen-Jun Chai, Yi-Zhou Jiang, Yin Liu, Xiao-Yan Ma, Gen-Hong Di, Xin Hu, Zhi-Ming Shao
Publikováno v:
Science Advances. 8
Immune checkpoint inhibitors exhibit limited response rates in patients with triple-negative breast cancer (TNBC), suggesting that additional immune escape mechanisms may exist. Here, we performed two-step customized in vivo CRISPR screens targeting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::efc180a2bd79809319390166da8e7339
https://doi.org/10.1126/sciadv.abl8247
https://doi.org/10.1126/sciadv.abl8247
Publikováno v:
The British journal of surgery. 109(12)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::587e6076a692613de25e14ba3a6bf9c8
https://pubmed.ncbi.nlm.nih.gov/36018290
https://pubmed.ncbi.nlm.nih.gov/36018290
Publikováno v:
SSRN Electronic Journal.
Purpose Disease progression during neoadjuvant systemic therapy for breast cancer indicates poor prognosis, while predictors of the clinical outcomes of these patients remain unclear. By comparing the clinical outcomes of patients with different patt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::974709bd087a08382e47c4dfcd11a324
https://doi.org/10.2139/ssrn.4313549
https://doi.org/10.2139/ssrn.4313549